Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chip-based genetic predisposition tests among most likely candidates for FDA regulation, staffers say.

This article was originally published in The Gray Sheet

Executive Summary

GENETIC TESTS BASED ON CHIP TECHNOLOGY ARE PRIME CANDIDATES FOR FDA REGULATION, agency staffers say. FDA has yet to formulate a policy on the genetic predisposition testing field, but if it does move to impose regulations, chip-based technologies would be a more likely target for regulation because they can be mass marketed to labs in a manner similar to test kits and analyzers.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel